.png){kind=icon}
Immuno-oncology has become a significant opportunity for oncology drug discovery and development. The ability to harness each person's unique immune system in a meaningful way to dampen the deadly effects of tumor cells has created the explosion of precision medicine. Integrate your flow cytometry, efficacy models, imaging, biomarker and companion diagnostics to quickly advance to the next milestone-because patients can't wait.
Preclinical immunotherapy
以富有意义的方式评估特定肿瘤模型研发所涉及的免疫效应细胞和介导个别疗法抗肿瘤反应的免疫效应细胞十分重要。 For many of our models, we have growth curves available, and we continue to build our database with treatment response to agents of interest like anti-CTLA-4, anti-PDL-1 and anti-PD-1 antibodies.
In addition to testing immune-modulating agents themselves or testing other agents in combination with immune-modulators, it is important to consider the impact of radiation therapy, which is being integrated into and increasingly investigated in combination with these immuno-oncology protocols. 表明放疗和免疫调节剂的远端效应以及直接联合的抗肿瘤作用的数据已提供了概念验证，并且正在临床前环境中对该高度利用的临床相关模式进行进一步的研究。
Clinical immuno-oncology
要使精准医疗取得成效，必须采用创新方法进行快速试验，并向合适的个人提供合适的疗法。 At Labcorp, we have proven experience in immuno-oncology studies, including over 100 protocols in the past five years, performed in 58 countries at more than 2,860 sites with over 19,750 patients.
Our commitment to immuno-oncology is also evident through our support of more than 70% of all FDA-approved companion diagnostic products. 作为近期关键性III期注册试验的一部分，我们的中心实验室是PD-L1表达试验的唯一供应商，这促成了FDA对一项新的OPDIVO®（nivolumab）诊断测试的审批。此外，我们同类最佳的伴随诊断能力支持TagrissoTM（osimertinib）及其EGFR突变试验以及免疫疗法Keytruda®（pembrolizumab）及其PD-L1伴随诊断通过了审批。
